AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 132 min read$AMGN

Khosla Rachna sold $1.3M of AMGN

Khosla Rachna (SVP, Business Development) sold 3,252 shares of AMGEN INC (AMGN) at an average of $414.05 ($412.57–$416.43, $1.35M total) across 2 trades over 2026-08-11 to 2026-08-13.

Original reporting
SEC EDGAR · Khosla Rachna
Published Aug 13, 2026, 11:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AMGN
Neutral
medium confidence
Mentioned
$AMGN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMGNNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price range, and that it was not under a pre-arranged 10b5-1 plan. No company performance, guidance, or regulatory/product event is mentioned.

02

Market read

Traders may note the insider selling activity, but there is no fundamental catalyst to drive a durable repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, traders should avoid over-weighting.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, covering sales from 2026-08-11 to 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for Amgen, reported by an SVP in business development.

Company-level read

Ticker impact

$AMGNNeutralMedium confidence
Context

Amgen SVP Khosla Rachna filed a Form 4 selling about 3,252 shares in open-market trades totaling $1.35M at $412.57 to $416.43.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

Form 4 insider sales are common and typically not predictive without accompanying company-specific news. The filing provides transaction details and timing, but no new catalyst for Amgen’s business.

Market effects

Sector

No direct read-through to biotech sector fundamentals from a single insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan could be interpreted as less “scheduled,” but the article provides no reason for the sale, limiting inference.

Key entities

  • issuer
    AMGN

    Amgen Inc., the Form 4 issuer for the insider sale.

  • insider
    Khosla Rachna

    SVP, Business Development at Amgen, reporting open-market sales.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMGN insider trading history →

Related articles

SEP 4
$AMGNMed

Amgen Slides as Tavneos Regulatory Pressure Weighs on Sentiment

Amgen (AMGN) shares fell 6.8% after U.K. regulators suspended Tavneos for new patients, citing concerns about its efficacy. The FDA also proposed withdrawing the drug in the U.S., raising regulatory risks. Tavneos contributes a small portion of Amgen's revenue. Insider sales, hedge fund activity, and analyst price targets were also noted.

quiverquant.com2 min
SEP 4
$AMGNMedAI 8/10

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?

Amgen (AMGN) reported Repatha reduced all-cause mortality by 20% in a secondary analysis of the VESALIUS-CV trial. The study involved over 12,000 high-risk adults without prior heart attacks or strokes. Repatha also lowered cardiovascular risks and LDL-C levels. Amgen aims to expand use before first major cardiovascular events, citing 15 years of clinical trials and global use in 9 million patients.

yahoo.com2 min
SEP 4
$NVSHighAI 8/10

NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?

Novartis (NVS) and Ionis (IONS) shares dropped after-hours Friday after a heart-disease trial for pelacarsen failed to show reduced risk of heart attacks or strokes, despite lowering lipoprotein(a). NVS fell 7%, IONS 10%. Amgen (AMGN) also dropped 5% as it develops a similar drug. NVS closed at $159.99. Both NVS and IONS have seen significant YTD changes, up 16% and down 27% respectively.

stocktwits.com2 min
SEP 4
$AZNMedAI 8/10

Topline results: Tezepelumab improves dysphagia frequency, severity in EoE

AstraZeneca and Amgen reported positive phase 3 trial results for tezepelumab (Tezspire) in treating eosinophilic esophagitis (EoE). The study showed improved dysphagia and histologic remission at weeks 24 and 52 compared to placebo. The companies plan to share data with regulators. Tezspire is already FDA-approved for severe asthma and chronic rhinosinusitis.

healio.com2 min
SEP 4
$AZNMedAI 8/10

AstraZeneca, Amgen Drug Hits Phase III EoE Goals

AstraZeneca and Amgen's TEZSPIRE met primary endpoints in a Phase III trial for eosinophilic esophagitis, showing significant improvements in histologic remission and dysphagia symptoms. The drug maintained efficacy through 52 weeks, with results planned for regulatory submission. TEZSPIRE is approved for severe asthma and chronic rhinosinusitis with nasal polyps.

mychesco.com2 min
SEP 4
$AMGNMed

Wells Fargo raises Amgen stock price target to $435 on drug trial outlook

Wells Fargo raised its price target for Amgen (AMGN) to $435, citing upcoming drug trial results. The stock is near its 52-week high and has gained 63% over the past year. A positive trial could add $10-$15 per share, while a negative result could reduce it by $20-$25. Amgen reported strong Q2 2026 earnings, with revenue of $10.1B and EPS of $6.29, exceeding estimates. Analysts remain optimistic despite a regulatory setback for its drug Tavneos.

investing.com1 min